Bioventus/$BVS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Bioventus
Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.
Ticker
$BVS
Sector
Primary listing
Employees
950
Headquarters
Website
Bioventus Metrics
BasicAdvanced
$480M
258.92
$0.03
0.83
-
Price and volume
Market cap
$480M
Beta
0.83
52-week high
$13.48
52-week low
$5.81
Average daily volume
458K
Financial strength
Current ratio
1.482
Quick ratio
0.89
Long term debt to equity
155.435
Total debt to equity
179.165
Interest coverage (TTM)
1.30%
Profitability
EBITDA (TTM)
61.783
Gross margin (TTM)
67.60%
Net profit margin (TTM)
0.33%
Operating margin (TTM)
7.73%
Effective tax rate (TTM)
43.44%
Revenue per employee (TTM)
$590,000
Management effectiveness
Return on assets (TTM)
3.64%
Return on equity (TTM)
1.39%
Valuation
Price to earnings (TTM)
258.92
Price to revenue (TTM)
0.837
Price to book
2.97
Price to tangible book (TTM)
-2.06
Price to free cash flow (TTM)
13.84
Free cash flow yield (TTM)
7.23%
Free cash flow per share (TTM)
0.518
Growth
Revenue change (TTM)
5.08%
Earnings per share change (TTM)
-103.99%
3-year revenue growth (CAGR)
4.32%
3-year earnings per share growth (CAGR)
-57.57%
What the Analysts think about Bioventus
Analyst ratings (Buy, Hold, Sell) for Bioventus stock.
Bulls say / Bears say
Bioventus posted Q4 2024 adjusted EPS of $0.15, beating the consensus estimate of $0.08, and delivered 13.5% revenue growth to $153.6 million, showcasing strong operational execution and margin improvement (Reuters)
In Q2 2025, non-GAAP EPS grew 31% to $0.21 and organic revenue rose 6.2% despite a reported decline of 2.4%, demonstrating resilient demand and improved profitability trends (Reuters)
The FDA granted 510(k) clearances for TalisMann™ and StimTrial™, expanding Bioventus’s presence in the peripheral nerve stimulation market expected to surpass $500 million by 2029, creating a significant high-growth opportunity (Reuters)
Q2 2025 reported revenue decreased 2.4% year-over-year to $147.7 million, underscoring ongoing pressure on the top line despite the impact of divestitures (Reuters)
Bioventus remained unprofitable on a GAAP basis in Q4 2024, recording a net loss of $0.16 million despite strong revenue growth, highlighting continued challenges with operating leverage (Reuters)
After Q2 2025 results, the company reaffirmed its full-year 2025 guidance instead of raising it, reflecting management’s cautious view on near-term growth prospects (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 6 Sept 2025.
Bioventus Financial Performance
Revenues and expenses
Bioventus Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Bioventus stock?
Bioventus (BVS) has a market cap of $480M as of September 16, 2025.
What is the P/E ratio for Bioventus stock?
The price to earnings (P/E) ratio for Bioventus (BVS) stock is 258.92 as of September 16, 2025.
Does Bioventus stock pay dividends?
No, Bioventus (BVS) stock does not pay dividends to its shareholders as of September 16, 2025.
When is the next Bioventus dividend payment date?
Bioventus (BVS) stock does not pay dividends to its shareholders.
What is the beta indicator for Bioventus?
Bioventus (BVS) has a beta rating of 0.83. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.